Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
Ipsen AB, Med Dept, Stockholm, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Endocrine Tumor Biology.
Ipsen AB, Med Dept, Stockholm, Sweden.
Lund Univ, Dept Endocrine & Sarcoma Surg, S-22185 Lund, Sweden.ORCID iD: 0000-0002-0953-1188
2019 (English)In: Patient Preference and Adherence, ISSN 1177-889X, E-ISSN 1177-889X, Vol. 13, p. 1799-1807Article in journal (Refereed) Published
Abstract [en]

Purpose: Evaluate patients' and nurses' experiences, including injection problem frequency, with the somatostatin analogues (SSAs) lanreotide autogel (R) (Somatuline (R) autogel (R), deep subcutaneous) and octreotide long-acting release (LAR) (Sandostatin (R) LAR (R), intramuscular) when treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: An observational, cross-sectional study across 2 NET centers in Sweden. Questionnaires based on participants' most recent injection experience were sent to patients with GEP-NETs treated with octreotide or lanreotide, and to nurses administering these treatments. Nurses were identified via patients completing their questionnaires. Resource use was sourced from Swedish prescription registry records. The planned sample size was 200, based on an estimated proportion of 0.50 and +/- 7% precision. Results: 119/156 patients (n=53, lanreotide; n=66, octreotide) and 43/53 nurses (n=22, lanreotide; n=21, octreotide) completed questionnaires. Despite smaller recruitment than planned, the endpoint precision was +/- 9% with 119 participants, and still considered reasonable. More octreotide-treated patients reported problems (18% vs none; P=0.001) and experienced moderate-to-high anxiety pre-injection (11% vs 2%). Patients had similar physical HRQoL scores overall (Short Form-12 mean composite scores: physical: 39.4 vs 37.6; mental: 50.7 vs 49.6). The mean number of lanreotide and octreotide doses dispensed per year were 11.1 and 12.6, respectively (P<0.05). In the lanreotide group, 28% self-injected, while 29% were not aware they could self-inject. In the octreotide group, 3% self-injected and 73% were unaware of the availability of an SSA for self-injection. Most patients (61%) felt well-informed about their disease and treatment. Nurses were generally experienced and felt confident and well-informed about giving SSA injections; however, only 12% felt well-informed about the disease and treatment. Conclusion: Those treated with lanreotide reported fewer injection problems and experienced less pre-injection anxiety than those treated with octreotide. SSA choice did not appear to affect patients' HRQoL. Some patients treated with octreotide were unaware of an SSA with the flexibility of self-injection.

Place, publisher, year, edition, pages
2019. Vol. 13, p. 1799-1807
Keywords [en]
gastroenteropancreatic neuroendocrine tumors, self-administration, somatostatin analogues
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-398536DOI: 10.2147/PPA.S213472ISI: 000491881000001PubMedID: 31695341OAI: oai:DiVA.org:uu-398536DiVA, id: diva2:1376525
Available from: 2019-12-09 Created: 2019-12-09 Last updated: 2019-12-09Bibliographically approved

Open Access in DiVA

fulltext(1134 kB)16 downloads
File information
File name FULLTEXT01.pdfFile size 1134 kBChecksum SHA-512
b0ad60714b8f4a4832162455a00fe28c90211c7534c3edeff035ea402b442ce43b9cd161f7813d4e134910330c8a262946ef06aa089eb89cba62ba6ebda128cd
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Almquist, Martin
By organisation
Endocrine Tumor Biology
In the same journal
Patient Preference and Adherence
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 16 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 29 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf